Use of alemtuzumab and tacrolimus monotherapy for cadaveric liver transplantation: With particular reference to hepatitis C virus

Transplantation

Volumn 78, Issue 7, 2004, Pages 966-971

  Marcos, Amadeo ^a   Eghtesad, Bijan ^a   Fung, John J ^a   Fontes, Paulo ^a   Patel, Kusum ^a   DeVera, Michael ^a   Marsh, Wallis ^a   Gayowski, Timothy ^a   Demetris, Anthony J ^a   Gray, Edward A ^a   Flynn, Bridget ^a   Zeevi, Adriana ^a   Murase, Noriko ^a   Starzl, Thomas E ^a,b  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; CYCLOSPORIN A; CYTOKINE; LYMPHOCYTE ANTIBODY; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RAPAMYCIN; TACROLIMUS;

ADULT; ALLOGRAFT; ARTICLE; CADAVER DONOR; COHORT ANALYSIS; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG MECHANISM; FEMALE; FOLLOW UP; GRAFT REJECTION; GRAFT SURVIVAL; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOLOGICAL TOLERANCE; IMMUNOSUPPRESSIVE TREATMENT; INFUSION; LIVER BIOPSY; LIVER TRANSPLANTATION; LYMPHOCYTE COUNT; LYMPHOCYTE DEPLETION; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NEPHROTOXICITY; NEUROTOXICITY; PRIORITY JOURNAL; SIDE EFFECT; SURVIVAL; WEANING;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; CADAVER; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HEPACIVIRUS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; TACROLIMUS; TRANSPLANTATION CONDITIONING;

EID: 6344256213     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.TP.0000142674.78268.01     Document Type: Article

References (20)

1. Starzl TE, Zinkernagel R. Transplantation tolerance from a historical perspective. Nat Rev Immunol 2001; 1: 233-239.
2. Starzl TE, Murase N, Abu-Elmagd K, et al. Tolerogenic immunosuppression for organ transplantation. Lancet 2003; 361: 1502-1510.
3. Shapiro R, Jordan M, Basu A, et al. Kidney transplantation under a tolerogenic regimen of recipient pre-treatment and low-dose postoperative immunosuppression, with subsequent weaning. Ann Surg 2003; 238: 520-527.
4. Hale G, Waldmann H, Dyer M. Specificity of monoclonal antibody Campath-1. Bone Marrow Transplant 1988; 3: 237-239.
5. Calne R, Friend P, Moffatt S, et al. Prope tolerance, perioperative Campath 1H, and low-dose cyclosporin monotherapy in renal allograft recipients. Lancet 1998; 351: 1701-1702.
6. Stuart FP, Leventhal JR, Kaufman DB, et al. Alemtuzumab facilitates prednisone free immunosuppression in kidney transplant recipients with no early rejection. Am J Transplant 2002; 2 (suppl 3): 397.
7. Knechtle SJ, Pirsch JD, H Fechner J Jr., et al. Campath-1H induction plus rapamycin monotherapy for renal transplantation: results of a pilot study. Am J Transplant 2003; 3: 722-730.
8. Kirk AD, Hale DA, Mannon RB, et al. Results from a human renal allograft tolerance trial evaluating the humanized CD52-specific monoclonal antibody alemtuzumab (CAMPATH-1H). Transplantation 2003; 76: 120-129.
9. Tzakis AG, Kato T, Nishida S, et al. Preliminary experience with Campath 1H (C1H) in intestinal and liver transplantation. Transplantation 2003; 75: 1227-1231.
10. Anonymous: Banff schema for grading liver allograft rejection: an international consensus document. Hepatology 1997; 25: 658-663.
11. Starzl TE, Zinkernagel RM. Antigen localization and migration in immunity and tolerance. N Engl J Med 1998; 339: 1905-1913.
12. Woodruff MFA, Anderson NF. Effect of lymphocyte depletion by thoracic duct fistula and administration of anti-lymphocytic serum on the survival of skin homografts in rats. Nature (London) 1963; 200: 702.
13. Monaco AP, Wood ML, Gray JG, et al. Studies on heterologous anti-lymphocyte serum in mice-II, effect on the immune response. J Immunol 1966; 96: 229.
14. Starzl TE, Marchioro TL, Porter KA, et al. The use of heterologous antilymphoid agents in canine renal and liver homotransplantation and in human renal homotransplantation. Surg Gynecol Obstet 1967; 124: 301-318.
15. Wu Z, Bensinger SJ, Zhang J, et al. Homeostatic proliferation is a barrier to transplantation tolerance. Nat Med 2004; 10: 87-92.
16. Auchincloss H. No tolerance for depletion. Nat Med 2004; 10: 21-23.
17. Neumann UP, Berg T, Bahra M, et al. Long-term outcome of liver transplants for chronic hepatitis C: a 10-year follow-up. Transplantation 2004; 77: 226-231.
18. Ghobrial RM, Steadman R, Gombein J, et al. A 10-year experience of liver transplantation for hepatitis C: analysis of factors determining outcome in over 500 patients. Ann Surg 2001; 34: 384-394.
19. Everson GT. Impact of immunosuppressive therapy on recurrence of hepatitis C. Liver Transpl 2002; 8 (suppl 1): S19-S27.
20. Demetris AJ, Ruppert K, Dvorchik I, et al. Real time monitoring of acute liver allograft rejection using the Banff Schema. Transplantation 2002; 74: 1290-1296.